AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

Lux, François; Long Tran, Vu; Thomas, Eloïse; Dufort, Sandrine; Rossetti, Fabien; Martini, Matteo; Truillet, Charles; Doussineau, Tristan; Bort, Guillaume; Denat, Franck; Boschetti, Fréderic; Angelovski, Goran; Detappe, Alexandre; Crémillieux, Yannick; Mignet, Nathalie; Doan, Bich‐Thuy; Larrat, Benoît; Mériaux, Sébastien; Barbier, Emmanuel; Roux, Stéphane; Fries, Peter; Müller, Andreas; Abadjian, Marie-Caline; J. Anderson, Carolyn; Canet‐Soulas, Emmanuelle; Bouziotis, Penelope; Barberi‐Heyob, Muriel; Frochot, Céline; Verry, Camille; Balosso, Jacques; J. Evans, Michael; Sidi‐Boumedine, Jacqueline; Janier, M.; T. Butterworth, Karl; J. McMahon, Stephen; M. Prise, Kevin; Aloy, Marie‐Thérèse; Ardail, Dominique; Rodriguez‐Lafrasse, Claire; Porcel, Erika; Lacombe, S.; Berbeco, Ross; Allouch, Awatef; Perfettini, Jean‐Luc; Chargari, Cyrus; Deutsch, Éric; Le Duc, Géraldine; Tillement, Olivier

doi:10.1259/bjr.20180365

Public

AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

Published in British Journal of Radiology • Sep 18, 2018

Authors:

François Lux

Vu Long Tran

Eloïse Thomas

Abstract

AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evi...

Subject

Medicine

Toxicity

Gadolinium

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!